[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
November 2017

Trends and Characteristics of US Medicare Spending on Repository Corticotropin

Author Affiliations
  • 1College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland
  • 2Department of Neurology, Oregon Health & Science University, Portland
  • 3Division of Arthritis & Rheumatic Diseases, Department of Medicine, Oregon Health & Science University, Portland
  • 4Division of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland
  • 5MS Center of Excellence–West, VA Portland Health Care System, Portland, Oregon
JAMA Intern Med. 2017;177(11):1680-1682. doi:10.1001/jamainternmed.2017.3631

Repository corticotropin (rACTH) injection (H. P. Acthar gel; Mallinckrodt Pharmaceuticals) has been under intense scrutiny for its very high cost.1,2 Because rACTH is approved for a variety of immunologic conditions prevalent in the US Medicare population, prescriptions for rACTH may have a significant financial impact on Medicare expenditures. The objectives of this study were to (1) estimate the cost of rACTH to the Medicare program, and (2) assess the within-specialty prescribing patterns for this medication.